Lilly Waiting On Phase III Data For Donanemab

 
• By Joseph Haas

Lilly no longer plans to complete an accelerated approval submission for Alzheimer’s candidate donanemab during Q1 following the CMS draft coverage decision for amyloid-targeting therapies.

Alzheimers_677117191_Atthapon-Raksthaput_1200.jpg
Lilly hopes confirmatory Phase III data will change CMS's view on amyloid-lowering drugs

More from Earnings

More from Business